Loading
A phase 2 trial of VS-7375, Cetuximab in pancreatic ductal adenocarcinoma, run by Verastem, Inc., now recruiting.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer is a phase 2 interventional study registered as NCT07644559 by Verastem, Inc., with 180 participants planned, started 2026-06-16 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares VS-7375, Verastem Oncology, Cetuximab.
Shares VS-7375, Verastem Oncology.
Shares VS-7375, Verastem Oncology, Cetuximab, Pancreatic ductal adenocarcinoma.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Metastatic pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/